Vedolizumab as induction and maintenance therapy for ulcerative colitis. - sprookjes - yvandenbroek - TriplyDB

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

http://www.wikidata.org/entity/Q34365566

about

Oral budesonide for induction of remission in ulcerative colitis Etrolizumab for induction of remission in ulcerative colitis The impact of biological interventions for ulcerative colitis on health-related quality of life Type I interferons for induction of remission in ulcerative colitis Etrolizumab for induction of remission in ulcerative colitis Anti-MAdCAM antibody for induction of remission in ulcerative colitis Vedolizumab for induction and maintenance of remission in ulcerative colitis Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes Advances in the development of new biologics in inflammatory bowel disease Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease Genetics and Therapeutics in Pediatric Ulcerative Colitis: the Past, Present and Future Vedolizumab Integrin-based therapeutics: biological basis, clinical use and new drugs Optimal management of steroid-dependent ulcerative colitis Hepatic manifestations of non-steroidal inflammatory bowel disease therapy Optimizing biologic treatment in IBD: objective measures, but when, how and how often?Promising biological therapies for ulcerative colitis: A review of the literature Future perspectives in target-specific immunotherapies of myasthenia gravis Current stage in inflammatory bowel disease: What is next?Medical Therapy of Active Ulcerative Colitis Management of ulcerative colitis Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease Pharmacologic therapy for inflammatory bowel disease refractory to steroids Patient considerations in the management of ulcerative colitis - role of vedolizumab Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2 Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer Therapeutic approaches for celiac disease Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists Review article: anti-adhesion therapies for inflammatory bowel disease Inflammatory pathways of importance for management of inflammatory bowel disease Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?

P2860

Q24186368-97C598ED-D8F3-4B85-AA95-0B03057C5D54 Q24186788-26E86CF9-9DAC-4BBA-8083-7DD7416EDE51 Q24187078-60F6E500-6B45-4372-96D3-65D0AC4B2F09 Q24187202-A6B6CAFE-6A52-4520-995A-53953B770E05 Q24187269-C7C03E90-E9A3-495C-8DC4-586E080E0C5D Q24187593-348CB400-A0E4-4E2B-BD20-CB10CCC0B33D Q24194423-85B2FD05-C448-4329-963E-04393CC648FA Q26745712-5700F9A9-22B5-4EA7-9FF0-773378F9A8DA Q26745725-5D8B3F6A-AA59-44DC-9AA3-B1E8DDC85F72 Q26745782-89904C58-C26C-4AAC-9C26-D851FCFBD74C Q26747744-A390F0DF-89CA-4D0C-850A-3D988AA95142 Q26748626-DC4A1B5D-37C5-4D9C-8EA9-6F26C301F30F Q26750190-A4398133-4254-41E3-960E-197026A5D006 Q26750456-57D28D17-D31E-4712-AA66-308F5589A329 Q26752768-3E031F20-EE8E-4B29-8A8C-896FEDF1DBE2 Q26765893-9AEED442-CEB6-4776-9551-A787B5709985 Q26769615-CAE83B09-B2F3-45DF-8158-26C62B5D4B74 Q26773026-5B3997C5-65AC-4997-97C2-5119448670CC Q26773203-EF327312-F21D-4646-8796-432D43B617D4 Q26773684-527F81E5-3C40-49CA-99F5-DEF835A77E99 Q26775064-7570BE1B-089E-46FA-B597-5435098A7C44 Q26776139-BF685EF5-F111-4F70-9E61-902A8D50B0BA Q26776225-5D988683-6E2D-4F78-AD9E-5051407AAA7C Q26777429-B9542939-4D51-40F1-8309-E825B4280831 Q26777729-71B4A0ED-3577-4F39-A07F-BB9C8181B7E6 Q26778250-B5B90BC0-4EA0-4A9C-9238-76F70623ADCE Q26785537-03F1E63D-DB35-4131-9EB7-E6882AFBD506 Q26786018-5CD5E01E-8D7B-44BD-8469-2E271CFCE965 Q26796415-F9FEB94D-7AE2-4370-8FC0-D77B57985BE4 Q26796432-C57CFA9C-C0EF-4FE2-B0E8-32ACF3FD36AE Q26798299-836118D9-5EEA-4606-8229-E8DBAEB8EE36 Q26822941-43110760-A32F-4226-9D44-F012F56CA972 Q26823237-7D51CB2C-DFAF-487C-9D89-D7196C0C2AA5 Q26825413-D07E4748-0E60-4DEE-9C94-311C8844768B Q26852514-34AD79B0-235E-4BD1-9C15-9C77952D2E3A Q26999078-FAE4C154-761C-4E86-A32F-139EC7FB9229 Q26999705-8ACDFB1B-6A0D-42DD-B25E-2ADC91804FE1 Q27005445-7AF0BEC2-9362-4ADC-91B6-42868572F337 Q27006683-C4CF8FA2-330A-4D22-8E11-4E66D1D26B09 Q27021612-8B1548D0-6FD9-4CD9-8D7F-AB706E9FFA54

P2860

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

http://www.wikidata.org/entity/Q34365566

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

@ast

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

@en

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

@nl

type

label

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

@ast

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

@en

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

@nl

prefLabel

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

@ast

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

@en

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

@nl

P1433

Q34365566-4900EB5A-5894-4743-9B06-D42167F9EADF

P1476

Q34365566-A7B6EB55-AAA8-4856-97BE-C894898DC6C1

P2093

Q34365566-0CCD7388-4483-45A8-B18A-680D990970FF

Q34365566-119ECED2-2450-427C-90C7-C98D58BB5ABA

Q34365566-16046610-0E48-4FAC-AEB6-5265C260E6C9

Q34365566-18CF3703-EC3E-46ED-A7E1-E67D44C62FD1

Q34365566-28F44D28-6772-499D-8202-6F83B8132D8A

Q34365566-48665130-EF19-4B67-AE68-1BBC36A12900

Q34365566-50227C6E-0F6B-4E00-94D5-56612CEFE03D

Q34365566-947B4BF4-11CD-46B0-BAE7-4A3697FB18CC

Q34365566-A768A81A-275A-4D9D-B927-6078168114E5

Q34365566-D9F8AADB-3989-4748-B2F6-6D00580CF4BC

P304

Q34365566-AAA0CD01-B69B-41C0-8C95-CF7E1CF68EF0

P31

Q34365566-2EDFC5B0-52EC-4016-A9A8-CB360D4B22A9

P356

Q34365566-565E0527-1F4D-4DC1-AFEB-B3C717408F06

P407

Q34365566-4F1855D0-9883-491A-95F4-7E525EE5CE70

P433

Q34365566-32168480-A425-4085-AD2D-8DC5613EC565

P478

Q34365566-B6D16842-ED9C-4AC5-9F76-4E77743E4505

P50

Q34365566-152667F4-1539-4B97-B25A-EC9E8F2BA22E

Q34365566-2E9DFEC2-47F3-43C9-99DC-F1F0017221CC

Q34365566-51993542-6679-4C07-8992-11F213FE6685

Q34365566-5DA149C0-0DA9-4FD0-B0B4-0E6013575BF3

Q34365566-FD2A1971-35B4-4C9A-AC90-A234CE555324

P577

Q34365566-A451A258-74DF-4003-8E0A-7834C6F836AA

P698

Q34365566-AE0D9959-4F29-4C42-B3C3-56BE736B2D13

P356

P1433

The New England Journal of Medicine

P1476

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

@en

P2093

Asit Parikh

http://www.w3.org/2001/XMLSchema#string

Bruce E Sands

http://www.w3.org/2001/XMLSchema#string

Catherine Milch

http://www.w3.org/2001/XMLSchema#string

GEMINI 1 Study Group

http://www.w3.org/2001/XMLSchema#string

Hyo-Jong Kim

http://www.w3.org/2001/XMLSchema#string

Irving Fox

http://www.w3.org/2001/XMLSchema#string

Jeffrey Axler

http://www.w3.org/2001/XMLSchema#string

Jing Xu

http://www.w3.org/2001/XMLSchema#string

Serap Sankoh

http://www.w3.org/2001/XMLSchema#string

Silvio Danese

http://www.w3.org/2001/XMLSchema#string

P304

699-710

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1215734

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Frédéric Colombel

Gert Van Assche

William Jeffery Sandborn

Brian G. Feagan

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23964932

http://www.w3.org/2001/XMLSchema#string